Convergent synthesis of hydrophilic monomethyl dolastatin 10 based drug linkers for antibody-drug conjugation.


Journal

Organic & biomolecular chemistry
ISSN: 1477-0539
Titre abrégé: Org Biomol Chem
Pays: England
ID NLM: 101154995

Informations de publication

Date de publication:
21 09 2019
Historique:
pubmed: 29 8 2019
medline: 4 3 2020
entrez: 29 8 2019
Statut: ppublish

Résumé

We report a modular approach to synthesize maleimido group containing hydrophilic dolastatin 10 (Dol10) derivatives as drug-linkers for the syntheses of antibody-drug conjugates (ADCs). Discrete polyethylene glycol (PEG) moieties of different chain lengths were introduced as part of the linker to impart hydrophilicity to these drug linkers. The synthesis process involved construction of PEG maleimido derivatives of the tetrapeptide intermediate (N-methylvaline-valine-dolaisoleucine-dolaproine), which were subsequently coupled with dolaphenine to generate the desired drug linkers. The synthetic method reported in this manuscript circumvents the use of highly cytotoxic Dol10 in its native form. By using trastuzumab (Herceptin®) as the antibody we have synthesized Dol10 containing ADCs. The presence of a discrete PEG chain in the drug linkers resulted in ADCs free from aggregation. The effect of PEG chain length on the biological activities of these Dol10 containing ADCs was investigated by in vitro cytotoxicity assays. ADCs containing PEG

Identifiants

pubmed: 31460552
doi: 10.1039/c9ob01639b
doi:

Substances chimiques

Antibodies, Monoclonal 0
Antineoplastic Agents 0
Depsipeptides 0
Immunoconjugates 0
dolastatin 10 EI946JT51X

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

8115-8124

Auteurs

Kanwen Yang (K)

Sanofi Global R&D, 153 Second Avenue, Waltham, MA 02139, USA. Pradeep.Dhal@sanofi.com.

Bo Chen (B)

Sanofi Global R&D, 153 Second Avenue, Waltham, MA 02139, USA. Pradeep.Dhal@sanofi.com.

Diego A Gianolio (DA)

Sanofi Global R&D, 153 Second Avenue, Waltham, MA 02139, USA. Pradeep.Dhal@sanofi.com.

James E Stefano (JE)

Sanofi Global R&D, 153 Second Avenue, Waltham, MA 02139, USA. Pradeep.Dhal@sanofi.com.

Michelle Busch (M)

Sanofi Global R&D, 153 Second Avenue, Waltham, MA 02139, USA. Pradeep.Dhal@sanofi.com.

Charlene Manning (C)

Sanofi Global R&D, 153 Second Avenue, Waltham, MA 02139, USA. Pradeep.Dhal@sanofi.com.

Kim Alving (K)

Sanofi Global R&D, 153 Second Avenue, Waltham, MA 02139, USA. Pradeep.Dhal@sanofi.com.

Richard C Gregory (RC)

Sanofi Global R&D, 153 Second Avenue, Waltham, MA 02139, USA. Pradeep.Dhal@sanofi.com.

William H Brondyk (WH)

Sanofi Global R&D, 153 Second Avenue, Waltham, MA 02139, USA. Pradeep.Dhal@sanofi.com.

Robert J Miller (RJ)

Sanofi Global R&D, 153 Second Avenue, Waltham, MA 02139, USA. Pradeep.Dhal@sanofi.com.

Pradeep K Dhal (PK)

Sanofi Global R&D, 153 Second Avenue, Waltham, MA 02139, USA. Pradeep.Dhal@sanofi.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH